ConductScience.org, home

Gene · 10039

PARP3: poly(ADP-ribose) polymerase family member 3

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. PARP3: poly(ADP-ribose) polymerase family member 3. Genes, record 10039. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/10039

On this page

Gene

Symbol
PARP3
HGNC
Name
poly(ADP-ribose) polymerase family member 3
HGNC
NCBI Gene ID
10039
NCBI Gene
HGNC ID
HGNC:273
HGNC
Ensembl
ENSG00000041880
NCBI Gene
Aliases
ADPRT3, ADPRTL2, ADPRTL3, ARTD3, IRT1, PADPRT-3, hPARP-3, pADPRT-3
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
Q9Y6F1Protein mono-ADP-ribosyltransferase PARP353316Ensembl, GeneID, HGNC

Source UniProt

Patents13

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
EP 4650780 A22025-11-1912759Q9Y6F1Espacenet
JP 2025517970 A2025-06-1212759Q9Y6F1Espacenet
JP 2024509935 A2024-03-0549Q9Y6F1Espacenet
US 11446398 B22022-09-2064539Q9Y6F1Espacenet
US 11446398 B22022-09-2064540Q9Y6F1Espacenet
JP 2022524081 A2022-04-27167510Q9Y6F1Espacenet
JP 2022524081 A2022-04-27167511Q9Y6F1Espacenet
US 9051553 B22015-06-094Q9Y6F1Espacenet
US 7754459 B12010-07-134Q9Y6F1Espacenet
JP 2002517231 A2002-06-188Q9Y6F1Espacenet

1 to 10 of 13

See all 13 patents

Drugs5

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
E-7016CHEMBL3527000PARP 1, 2 and 3 inhibitorINHIBITORChEMBL
OLAPARIBCHEMBL521686PARP 1, 2 and 3 inhibitorINHIBITORChEMBL
RUCAPARIBCHEMBL1173055PARP 1, 2 and 3 inhibitorINHIBITORChEMBL
RUCAPARIB CAMSYLATECHEMBL3833368PARP 1, 2 and 3 inhibitorINHIBITORChEMBL
VELIPARIBCHEMBL506871PARP 1, 2 and 3 inhibitorINHIBITORChEMBL

Trials511

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

NIH grants468

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitlePARP3 papersNewest fiscal year
P01CA092584Structural Cell Biology of DNA Repair Machines122025
R01DK069710The Role of Nuclear PARPs in Signal-Regulated Transcription102025
R01GM117275Protein N-terminal Methylation Mechanisms and Inhibition92025
P30CA023168Cancer Center Support Grant72025
P50CA136393Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancer62025
P30CA008748Cancer Center Support Grant52025
T32CA009110Training in Areas Fundamental to Cancer Research52025
P30CA014051Cancer Center Support (Core) Grant42025
P20GM113117Chemical Biology of Infectious Disease32025
P30CA016672Cancer Center Support Grant32025

1 to 10 of 468Source NIH's project files

See all 468 nih grants

Papers882

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
PARP3 Promotes SARS-CoV-2 Replication via Interaction with the Viral Nucleocapsid Protein.Kobe J Med Sci202642805913PubTator, text miningPubMed
Optimization of a Second-Generation, Highly Selective Polθ/PARP1 Dual Inhibitor with Improved Pharmacokinetics and Potent Activity against HR-Deficient Tumors.J Med Chem202642720455PubTator, text miningPubMed
NDRG1 expression in cancers confers dependence on DNA damage repair and sensitivity to quinacrine.Sci Signal202642479816PubTator, text miningPubMed
Immunometabolic reprogramming of Mycobacterium tuberculosis-responsive memory CD4+ T cell subsets is linked to long-term protective immunity.Front Tuberc202642368172PubTator, text miningPubMed
A stage-resolved neuron-glia transcriptional atlas reveals a glial inflammatory pivot in epilepsy.Acta Neuropathol Commun202642324481PubTator, text miningPubMed
[PARP3: a Swiss army knife orchestrating DNA repair, cancer aggressiveness and cell differentiation].Med Sci (Paris)202642213971PubTator, text miningPubMed
Molecular Insights into Parkinson's Disease Progression: A Multi-omics Analysis of the Substantia Nigra Pars Compacta across Braak Stages.Exp Neurobiol202642130054PubTator, text miningPubMed
Differential sensitivity of MCPH1- and BRCA2-deficient cancer cells to PARP-1 inhibition.PLoS One202641931484PubTator, text miningPubMed
Reversible RNA ADP-ribosylation on uracil bases.Nucleic Acids Res202641914495PubTator, text miningPubMed
Ultrasound-Assisted Synthesis and Biological Profiling of 1,3,5-Triazine Derivatives with Antiproliferative Activity in Triple-Negative Breast Cancer.Curr Issues Mol Biol202641899470PubTator, text miningPubMed

1 to 10 of 882

See all 882 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/10039

GET https://conductscience.org/api/genes/v1/10039/patents